Jasper Therapeutics Q3 loss smaller than estimates

Jasper Therapeutics

10/11/2025 13:08

Overview

Jasper Q3 loss per share beats analyst expectations despite net loss of $18.7 mln

Company completed $30 mln stock offering, extending cash runway through H1 2026

Outlook

Company plans to report final conclusions from investigation into BEACON study anomalies  in Q4 2025

Company expects initial data from ETESIAN study in allergic asthma in Q4 2025

Jasper aims to complete dose selection for Phase 2b CSU study by mid-2026

Result Drivers

FINANCIAL POSITION - $30 mln stock offering completed, extending cash runway through H1 2026

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
Beat
-$1.13
-$1.21 (7 Analysts)
Q3 Net Income
-$18.70 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Jasper Therapeutics Inc is $10.50, about 83% above its November 7 closing price of $1.78

Press Release: ID:nGNXyRBV4

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)